Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

Author's Avatar
Apr 24, 2023

Janux+Therapeutics%2C+Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will participate at two upcoming investor conferences and be available for 1x1 meetings. Details of the conferences are as follows: